UCL news

Professor Bart De Strooper (UK Dementia Research Institute at UCL) has been awarded an honorary CBE for his services to dementia research in the UK and internationally.

A global clinical trial for a new Huntington’s disease treatment has posted positive results today, announced by trial sponsor uniQure and UCL scientists.

Researchers across UCL are applying artificial intelligence in powerful ways to accelerate Alzheimer’s diagnosis, track disease progression and develop new treatments.

Three UCL academics have received a combined total of over £7 million to support projects in lung cancer research, the link between Parkinson’s and dementia and how brain ageing affects dementia risk.

A major UCL-led clinical trial, aiming to transform the diagnosis of Alzheimer’s disease through a simple blood test, is now welcoming its first participants who will be recruited via memory clinics across the UK.

Two new studies of former rugby players, involving UCL researchers, found no cases of early-onset dementia but did find potential signs of increased risk of developing dementia later on.

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer’s therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has licensed the immunotherapy drug, Lecanemab, for use in the early stages of Alzheimer’s disease in the UK, following decades of work supported by UCL research.

Baroness Gillian Merron, the Health Minister responsible for life sciences and innovation toured some of UCL’s life sciences facilities to see first-hand how research is helping to tackle some of the world’s biggest health challenges.

Biotech company AstronauTx, aiming to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders, has closed a £48m ($61m) Series A financing.

Ten months ago, UCL’s Professor Sir John Hardy hailed the Lecanemab trial as the “beginning of the end” for Alzheimer’s disease, but this was just the start of a series of exciting developments – with UCL experts at the forefront.

A team of researchers led by Professor Bart De Strooper (UK Dementia Research Institute at UCL, and VIB-KU Leuven) and Dr Sriram Balusu (VIB-KU Leuven) have discovered how neurons die in Alzheimer’s disease.

Professor Siddharthan Chandran, a world-leading expert in neurodegenerative diseases, will become the new Director of the UK Dementia Research Institute (UK DRI), based at UCL, from 1 October 2023.

Researchers from UCL, the UK Dementia Research Institute, Imperial College London and Newcastle University, are involved in a major new collaboration to develop a technology that could help identify people at risk of developing dementia by analysing their sleep patterns.

UCL’s new world-class neuroscience building has reached its highest point in construction, which was celebrated with a ‘topping out’ ceremony today.